Table 1 Summary of patient demographic, clinical, follow-up data as well as immunohistochemical and in-situ hybridisation profiles. The immunohistochemical profile is summarised as follows: quick score 0 = −, 1–2 = +, 3–5 = ++, 6-8 = +++. *Strong diffuse nuclear and cytoplasmic staining in >70 % of tumour cells
Case 1 | Case 2 | |||
|---|---|---|---|---|
Age | 59 | 54 | ||
Sex | Male | Male | ||
TNM | T2 N2b | T1 N2b | ||
Treatment | Concomitant chemo-radiotherapy | Concomitant chemo-radiotherapy | ||
Follow-up | 18 months | 6 months | ||
Immunophenotype | Differentiated component | Undifferentiated component | Differentiated component | Undifferentiated component |
AE1/3 | +++ | +++ | +++ | +++ |
CK5/6 | +++ | + | +++ | +++ |
CK7 | - | - | ++ | - |
CK8/18 | +++ | + | ++ | ++ |
CK19 | +++ | - | +++ | ++ |
CK20 | - | ++ | - | - |
Vimentin | +++ | ++ | ++ | ++ |
Ki-67 | +++ | ++ | +++ | +++ |
p63 | +++ | +++ | +++ | +++ |
p16* | +++ | +++ | +++ | +++ |
HR-HPV ISH | Fine, punctate | Strong, diffuse | Strong, diffuse | Fine, punctate |
TILs | +++ (>75 %) | + (25-50 %) | + (25-50 %) | ++ (50-75 %) |